Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 6 (June)

1. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease.
   Proc Natl Acad Sci U S A, 102(22): 8024-9. [Abstract] [Full-text]
2. Three-dimensional stereotactic surface projection study of orthostatic hypotension and brain perfusion image in Parkinson's disease.
   Acta Neurol Scand, 112(1): 36-41. [Abstract] [Full-text]
3. The prevalence of PD in a nutritionally deficient rural population in China.
   Acta Neurol Scand, 112(1): 29-35. [Abstract] [Full-text]
4. Prevalence of Parkinson's disease in the L'Aquila district, central Italy.
   Acta Neurol Scand, 112(1): 24-8. [Abstract] [Full-text]
5. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
   J Neurochem, 93(6): 1482-6. [Abstract] [Full-text]
6. Methylenetetrahydrofolate reductase C677T genotype and PD.
   Ann Neurol, 57(6): 927-30. [Abstract] [Full-text]
7. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.
   Ann Neurol, 57(6): 918-21. [Abstract] [Full-text]
8. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype.
   J Biol Chem, 280(23): 22530-9. [Abstract] [Full-text]
9. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
   Mov Disord, 20(6): 734-9. [Abstract] [Full-text]
10. Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements.
    Mov Disord, 20(6): 694-704. [Abstract] [Full-text]
11. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
    Mov Disord, 20(6): 726-33. [Abstract] [Full-text]
12. Smell identification ability in twin pairs discordant for Parkinson's disease.
    Mov Disord, 20(6): 687-93. [Abstract] [Full-text]
13. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.
    Mov Disord, 20(6): 680-6. [Abstract] [Full-text]
14. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
    J Neuropsychiatry Clin Neurosci, 17(2): 214-20. [Abstract] [Full-text]
15. The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure.
    J Clin Epidemiol, 58(7): 674-9. [Abstract] [Full-text]
16. Cholinergic cortical circuits in Parkinson's disease and in progressive supranuclear palsy: a transcranial magnetic stimulation study.
    Exp Brain Res, 163(1): 128-31. [Abstract] [Full-text]
17. Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems.
    Neurosurg Rev, 28(3): 179-86; discussion 187. [Abstract] [Full-text]
18. Diffusion-weighted imaging-guided resection of intracerebral lesions involving the optic radiation.
    Neurosurg Rev, 28(3): 188-95. [Abstract] [Full-text]
19. Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
    Neuroscience, 133(3): 831-40. [Abstract] [Full-text]
20. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
    Neuron, 46(6): 857-68. [Abstract] [Full-text]
21. The biochemistry of Parkinson's disease.
    Annu Rev Biochem, 74: 29-52. [Abstract] [Full-text]
22. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease.
    Neurosignals, 14(1): 6-22. [Abstract] [Full-text]
23. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
    Arch Neurol, 62(6): 917-21. [Abstract] [Full-text]
24. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Arch Neurol, 62(6): 905-10. [Abstract] [Full-text]
25. Parkinson's tremor mimicking ventricular tachycardia.
    Age Ageing, 34(4): 410-1. [Abstract] [Full-text]
26. Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease.
    Biochim Biophys Acta, 1741(1): 65-74. [Abstract] [Full-text]
27. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
    J Neurol Neurosurg Psychiatry, 76(7): 934-9. [Abstract] [Full-text]
28. Striatal deformities of the hand and foot in Parkinson's disease.
    Lancet Neurol, 4(7): 423-31. [Abstract] [Full-text]
29. Therapeutic role of coenzyme Q(10) in Parkinson's disease.
    Pharmacol Ther, 107(1): 120-30. [Abstract] [Full-text]
30. Patterns of lung volume use during an extemporaneous speech task in persons with Parkinson disease.
    J Commun Disord, 38(5): 331-48. [Abstract] [Full-text]
31. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Neurol Res, 27(5): 533-9. [Abstract] [Full-text]
32. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients.
    Neurosci Lett, 384(3): 327-9. [Abstract] [Full-text]
33. To die or grow: Parkinson's disease and cancer.
    Trends Neurosci, 28(7): 348-52. [Abstract] [Full-text]
34. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.
    Brain, 128: 1498-510. [Abstract] [Full-text]
35. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Brain, 128: 1605-12. [Abstract] [Full-text]
36. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Trends Pharmacol Sci, 26(7): 341-4. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.